Skip to main content

Market Overview

Roche's Tocilizumab Injection Wins FDA Approval For Lung Disease

  • The FDA has approved Roche Holdings AG's (OTCQX: RHHBY) Actemra/RoActemra (tocilizumab) for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
  • Systemic sclerosis, also known as scleroderma, is an autoimmune disease causing tissues of the skin and lungs to thicken and harden.
  • This subcutaneous injection is the sixth FDA-approved indication for Actemra/RoActemra since its launch in the U.S. in 2010.
  • The company says that the treatment is the first biologic therapy approved by the FDA to treat the disease.
  • Last month, Oxford researchers Actemra (tocilizumab) cuts the risk of death among patients hospitalized with severe COVID-19, shortens the time to recovery and reduces the need for mechanical ventilation.
  • Price Action: RHHBY shares are up 0.4% at $40.5 in premarket trading on the last check Friday.

Related Articles (RHHBY + RHHBF)

View Comments and Join the Discussion!

Posted-In: Lung Disease Systemic SclerosisBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at